All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Why should frailty be considered a dynamic factor in MM and when should it be assessed?

Jan 27, 2023
Learning objective: After reading this article, learners will be able to cite a new clinical development in the monitoring of frailty in patients with multiple myeloma.

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Hira Mian, McMaster University, Hamilton, CA. We asked, Why should frailty be considered a dynamic factor in multiple myeloma (MM) and when should it be assessed?

Why should frailty be considered a dynamic factor in MM and when should it be assessed?

In this interview, Mian looks at frailty as a predictor of outcomes, such as overall survival and toxicity rates, in patients with MM. Mian outlines how in current practice frailty is often only assessed at diagnosis and therefore there is a gap in understanding how frailty changes, as well as the changing need for therapy escalation or de-escalation. Mian goes on to outline their research study entitled “Need for dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort study”, and concludes with the results and implications of this study, including the dynamic nature of frailty and the optimum time to reassess frailty post-diagnosis, which ultimately can help tailor treatment.